Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais

Detalhes bibliográficos
Autor(a) principal: Silva,Roberta Barros da
Data de Publicação: 2021
Outros Autores: Silva,Thales Philipe Rodrigues da, Sato,Ana Paula Sayuri, Lana,Francisco Carlos Felix, Gusmão,Josianne Dias, Souza,Janaina Fonseca Almeida, Matozinhos,Fernanda Penido
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista de Saúde Pública
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102021000100249
Resumo: ABSTRACT OBJECTIVE To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied. RESULTS The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied). CONCLUSION This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population.
id USP-23_5da0cd3127da9a4fa0ea808168a538a6
oai_identifier_str oai:scielo:S0034-89102021000100249
network_acronym_str USP-23
network_name_str Revista de Saúde Pública
repository_id_str
spelling Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas GeraisCoronavirus Infections, prevention & controlVaccines, adverse effectsClinical Trials Data Monitoring CommitteesABSTRACT OBJECTIVE To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied. RESULTS The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied). CONCLUSION This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population.Faculdade de Saúde Pública da Universidade de São Paulo2021-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102021000100249Revista de Saúde Pública v.55 2021reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USP10.11606/s1518-8787.2021055003734info:eu-repo/semantics/openAccessSilva,Roberta Barros daSilva,Thales Philipe Rodrigues daSato,Ana Paula SayuriLana,Francisco Carlos FelixGusmão,Josianne DiasSouza,Janaina Fonseca AlmeidaMatozinhos,Fernanda Penidoeng2021-11-08T00:00:00Zoai:scielo:S0034-89102021000100249Revistahttp://www.scielo.br/scielo.php?script=sci_serial&pid=0034-8910&lng=pt&nrm=isoONGhttps://old.scielo.br/oai/scielo-oai.phprevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2021-11-08T00:00Revista de Saúde Pública - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
title Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
spellingShingle Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
Silva,Roberta Barros da
Coronavirus Infections, prevention & control
Vaccines, adverse effects
Clinical Trials Data Monitoring Committees
title_short Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
title_full Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
title_fullStr Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
title_full_unstemmed Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
title_sort Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
author Silva,Roberta Barros da
author_facet Silva,Roberta Barros da
Silva,Thales Philipe Rodrigues da
Sato,Ana Paula Sayuri
Lana,Francisco Carlos Felix
Gusmão,Josianne Dias
Souza,Janaina Fonseca Almeida
Matozinhos,Fernanda Penido
author_role author
author2 Silva,Thales Philipe Rodrigues da
Sato,Ana Paula Sayuri
Lana,Francisco Carlos Felix
Gusmão,Josianne Dias
Souza,Janaina Fonseca Almeida
Matozinhos,Fernanda Penido
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva,Roberta Barros da
Silva,Thales Philipe Rodrigues da
Sato,Ana Paula Sayuri
Lana,Francisco Carlos Felix
Gusmão,Josianne Dias
Souza,Janaina Fonseca Almeida
Matozinhos,Fernanda Penido
dc.subject.por.fl_str_mv Coronavirus Infections, prevention & control
Vaccines, adverse effects
Clinical Trials Data Monitoring Committees
topic Coronavirus Infections, prevention & control
Vaccines, adverse effects
Clinical Trials Data Monitoring Committees
description ABSTRACT OBJECTIVE To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied. RESULTS The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied). CONCLUSION This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population.
publishDate 2021
dc.date.none.fl_str_mv 2021-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102021000100249
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102021000100249
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.11606/s1518-8787.2021055003734
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Faculdade de Saúde Pública da Universidade de São Paulo
publisher.none.fl_str_mv Faculdade de Saúde Pública da Universidade de São Paulo
dc.source.none.fl_str_mv Revista de Saúde Pública v.55 2021
reponame:Revista de Saúde Pública
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Revista de Saúde Pública
collection Revista de Saúde Pública
repository.name.fl_str_mv Revista de Saúde Pública - Universidade de São Paulo (USP)
repository.mail.fl_str_mv revsp@org.usp.br||revsp1@usp.br
_version_ 1748936506548944896